Introduction {#Sec1}
============

Ketone bodies (acetoacetate, 3-hydroxybutyrate, acetone), predominantly produced in the liver, provide extrahepatic organs such as heart and brain with energy when glucose supply is limited (Sass [@CR21]). Any enzyme malfunction in ketone body utilization (ketolysis) could lead to a buildup of unused ketone bodies and result in ketoacidosis. Succinyl-CoA:3-ketoacid CoA transferase (SCOT; gene name *OXCT1*; EC 2.8.3.5) catalyzes the first and rate-determining step of ketolysis (Fukao et al [@CR7]; Kassovska-Bratinova et al [@CR13]). SCOT is a member of the CoA transferase family I that activates acetoacetate by transferring a CoA moiety from succinyl-CoA to form acetoacetyl-CoA. Acetoacetyl-CoA is further metabolized by acetoacetyl-CoA thiolase into two acetyl-CoA molecules which enter the citric acid cycle for energy production (Williamson et al [@CR26]). SCOT is a mitochondrial enzyme expressed in all extrahepatic tissues, but abundant in the heart, brain and kidney (Fukao et al [@CR6]). There exists also a testis-specific isoform SCOT-t (gene name *OXCT2*), sharing 74 % amino acid identity with SCOT (Tanaka et al [@CR25]).

Mutations in the human *OXCT1* gene on chromosome location 5p13 result in the rare autosomal recessive deficiency of SCOT (OMIM 245050) (Mitchell and Fukao [@CR16]). SCOT-deficient patients, often with neonatal onset, present with recurrent ketoacidosis episodes that could be life-threatening, but with no symptoms between episodes (Niezen-Koning et al [@CR18]). The number of reported cases is few, and symptoms, which may vary among individuals, include vomiting, lethargy and tachypnea, as well as unconsciousness caused by severe ketoacidosis (Berry et al [@CR3]; Sakazaki et al [@CR20]; Snyderman et al [@CR22]). Permanent ketosis or ketonuria is a characteristic symptom but may be absent in patients retaining residual SCOT activity (Fukao et al [@CR10]; Fukao et al [@CR11]; Fukao et al [@CR8]). Approximately 30 affected probands were reported to date and 24 mutations identified (Table [1](#Tab1){ref-type="table"}). Here we report the crystal structure of human SCOT, and present an interactive mapping of missense mutations to understand the molecular basis of SCOT deficiency.Table 1Mutations reported for the human OXCT1 gene causing SCOT deficiency. Additional phenotype information can be found in the [supplementary text](#MOESM1){ref-type="media"}\#DNA changeExonMutation siteMutated residueProtein changeConservationReference1^a,c,d^c.112C \> T^b^2Arg38Cysp.R38C(Alkén [@CR1])2^c^c.335T \> A^b^4Val112Aspp.V112DSemi-Conserved(Alkén [@CR1])3c.398T \> A4Val133Glup.V133ESemi-Conserved(Song et al [@CR24])4c.644C \> T6Ala215Valp.A215VConserved(Fukao et al [@CR11])5c.656G \> A6Gly219Glup.G219EConserved(Fukao et al [@CR7])6c.661G \> A6Val221Metp.V221MSemi-Conserved(Fukao et al [@CR7])7c.677G \> A7Ser226Asnp.S226NSemi-Conserved(Fukao et al [@CR11])8^c^c.785C \> G8Pro262Argp.P262RConservedSass et al (unpublished)9^c^c.802C \> T8Arg268Cysp.R268CConservedSass et al (unpublished)10c.803G \> A8Arg268Hisp.R268HConserved(Fukao et al [@CR9])11c.971G \> A10Gly324Glup.G324EConserved(Fukao et al [@CR7])12c.980T \> C10Leu327Prop.L327PConserved(Fukao et al [@CR11])13^†^c.1162A \> G^b^12Met388Valp.M388VConserved(Alkén [@CR1])14c.1210G \> T13Val404Phep.V404FConserved(Fukao et al [@CR11])15c.1213T \> C13Ser405Prop.S405PConserved(Fukao et al [@CR11])16^†‡b^14Leu429Phep.L429FConserved(Alkén [@CR1])17c.1304C \> A14Thr435Asnp.T435NConserved(Fukao et al [@CR10]; Fukao et al [@CR8])18c.1367G \> T15Cys456Phep.C456FConserved(Song et al [@CR24])19c.1402C \> T15Arg468Cysp.R468CLow-conserved(Fukao et al [@CR11])Insertion, deletion, frameshift mutations20c.649C \> T6Arg217Xp.R217XSemi-Conserved(Longo et al [@CR14])21c.817G \> T8Glu273Xp.E273XVariable(Fukao et al [@CR11])22c.848C \> G9Ser283Xp.S283XConserved(Yamada et al [@CR27])23c.658-666dup6Asn220-Ile222p.N220-I222 dupConserved (Asn220), Semi-conserved (Val221,Ile222)(Fukao et al [@CR10])24c.1561T \> C^b^6X521RArgAdding 20 AAs(Alkén [@CR1])^**a**^The R38C mutation resides in the N-terminus of the protein that is disordered and not modelled in the crystal structure^b^DNA change in the R38C, V122D, M388V and X521R mutations are deduced from amino acid substitution. The DNA change in the L429F mutation is not reported and cannot be deduced from amino acid substitution^c^These mutations have not been confirmed as pathogenic by expression analysis^d^R38C and L429F mutations coexisted in one mutant allele

Experimental procedures {#Sec2}
=======================

Expression, purification & crystallization {#Sec3}
------------------------------------------

DNA fragment encoding the catalytic domain of human SCOT (aa 40--520; GenBank entry 4557817) was subcloned into pNIC-CTHF vector incorporating a C-terminal His~6~-tag. The plasmid was transformed into BL21(DE3)-R3-pRARE2, cultured in Terrific Broth at 37 °C, and induced with 0.5 mM IPTG. Cells were homogenized in lysis buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5 % glycerol, 5 mM imidazole, 1 mM PMSF, 0.5 mM TCEP), centrifuged to remove cell debris, and the supernatant was purified by Nickel affinity (HisTrap 1 ml GE/Amersham) and size exclusion (HiLoad 16/60 Superdex S200) chromatography. Purified protein was concentrated to 21 mg/ml and stored in 10 mM HEPES pH 7.5, 500 mM NaCl, 5 % (w/v) glycerol and 0.5 mM TCEP at −80 °C. Crystals were grown by vapour diffusion at 20 °C, in sitting drops mixing 100 nl protein pre-incubated with 2 mM acetyl-CoA and 300 nl reservoir solution containing 0.20 M sodium chloride, 0.1 M Tris pH 9.0 and 25 % (w/v) polyethylene glycol 3,350. Crystals were cryo-protected in mother liquor containing 20 % (w/v) glycerol and flash-frozen in liquid nitrogen.

Data collection & structure determination {#Sec4}
-----------------------------------------

Diffraction data to maximum resolution of 2.20 Å were collected on beamline X10A at the Swiss Light Source, and processed using the CCP4 Program suite (CCP4 [@CR4]). SCOT crystallized in the P2~1~ space group with four molecules in the asymmetric unit (Supplementary Table [1](#MOESM1){ref-type="media"}). The structure of human SCOT was solved by molecular replacement with PHASER (McCoy et al [@CR15]), using the pig heart structure as search model (PDB code 1M3E)(Bateman et al [@CR2]). Initial automated model building was performed with ARP/wARP (Perrakis et al [@CR19]), followed by cycles of iterative manual model building with COOT (Emsley and Cowtan [@CR5]) and REFMAC5 refinement (Murshudov et al [@CR17]). The refined model consists of protein residues 40--285 and 297--519. No electron density was observed for part of the inter-domain linker (residues 286--296). No ligand density for acetyl-CoA was found in the active site though it was added during crystallization. Structure factors and coordinates were deposited in the Protein Data Bank under the accession code 3DLX.

Results and discussion {#Sec5}
======================

We have determined the crystal structure of human SCOT which exhibits a homodimer architecture containing two active sites (Fig. [1](#Fig1){ref-type="fig"}). Each monomer consists of the amino-terminal (N-; aa 40--272) and carboxy-terminal (C-; aa 298--510) domains, connected by a linker region (aa 273--297). The N- and C-domains share a common α/β structural fold for CoA transferase family I members (Heider [@CR12]), as previously seen in the pig SCOT structure (89 % sequence identity)(Bateman et al [@CR2]). The active site of each monomer is situated at the interface of the two domains, where a strictly conserved residue Glu344 (Fig. [1](#Fig1){ref-type="fig"}, orange sticks) attacks the incoming succinyl-CoA substrate and forms an enzyme-CoA thioester intermediate, as an integral part of the catalytic mechanism (Solomon and Jencks [@CR23]). Residues in the active site of human SCOT are also conserved in the testis-specific isoform SCOT-t, suggesting it may have enzymatic activity.Fig. 1Ribbon diagram of human SCOT structure illustrating the homodimeric assembly. The two monomeric subunits **a** and **b** are coloured distinctively (*blue* and *magenta*). The active site in each subunit is indicated by the Glu344 residue shown in *orange sticks*

To date, three nonsense, two insertion and 19 missense mutations leading to SCOT deficiency are known from literature or newly reported here (Table [1](#Tab1){ref-type="table"} and [Supplementary text](#MOESM1){ref-type="media"}), although six missense mutations have not been confirmed as pathogenic mutations by expression analysis. There is a polymorphism c.173C \> T (T58M) which retains full enzyme activity (Song et al [@CR24]). The three nonsense mutations (R217X, E273X, S283X) are expected to cause premature translation termination, resulting in truncated SCOT proteins that lack completely the C-domain and hence abolish part of the active site. Another mutation c.1561T \> C at the termination codon results in X521R and adds 20 amino acids in the C terminus of SCOT peptide (Alkén [@CR1]). The missense mutations are broadly distributed between the N- and C-domains of the protein, although two clusters of 'mutational hotspots' can be observed (Fig. [2](#Fig2){ref-type="fig"}). One cluster is close to the interface between two SCOT subunits in a dimer. A duplication mutation (N220-I222dup) is also present in this region (Fukao et al [@CR10]). The other cluster is located in secondary structure elements that make up the active site and CoA-binding site of the enzyme.Fig. 2Clustering of human SCOT missense mutations, displayed in the same colour scheme as Fig. [1](#Fig1){ref-type="fig"}. The positions of amino acid mutations are indicated by *small spheres* and *numbered* according to Table [1](#Tab1){ref-type="table"}. Mutations that affect the monomeric fold or dimerization interaction are coloured *red* and *yellow* respectively

The mapping of missense mutations onto the human SCOT structure allows us to classify their potential structural consequences broadly into three types. In the first type, amino acids tightly packed in the enzyme are substituted to bulkier and/or charged residues (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, *\#2--7,11,14,16,17*). This likely results in severe steric and electrostatic clashes in the local environment which in turn can compromise severely the folding, architecture and stability of the enzyme. These mutants often result in the more severe phenotype (permanent acidosis), consistent with their much diminished enzyme activity (Fukao et al [@CR7]; Song et al [@CR24]). The second type disrupts the integrity of a secondary structure element, either by introducing a conformationally-restrained residue (e.g. Pro, Gly) into an α-helix/β-strand (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, *\#12,15*), or by removing such residues from their critical involvement in a loop/turn segment (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, *\#8*). The third type involves the substitution of arginine residues where their guanidinium side-chains are involved in salt bridge formation. These charged interactions contributed to stabilizing two neighbouring regions in 3D space that are distant apart in the polypeptide sequence. Substitution of arginine to a weakly positive-charged (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, *\#10*) or uncharged amino acid (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, *\#9,19*) will abolish these salt bridges. Though retaining partial enzyme activities, these mutant proteins are thermally less stable compared to wild-type (Fukao et al [@CR9]; Fukao et al [@CR11]).
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